KR890009402A - 피페리디닐시클로펜틸헵텐산 유도체를 함유한 수용성 제제 - Google Patents
피페리디닐시클로펜틸헵텐산 유도체를 함유한 수용성 제제 Download PDFInfo
- Publication number
- KR890009402A KR890009402A KR1019880017106A KR880017106A KR890009402A KR 890009402 A KR890009402 A KR 890009402A KR 1019880017106 A KR1019880017106 A KR 1019880017106A KR 880017106 A KR880017106 A KR 880017106A KR 890009402 A KR890009402 A KR 890009402A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- hydrochloride
- cyclodextrin
- formulation
- piperidinylcyclopentylheptenic
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 10
- 239000000203 mixture Substances 0.000 title claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims 2
- JAIYKLJZOBJGSG-UHFFFAOYSA-N 2-cyclopentyl-3-piperidin-1-ylhept-2-enoic acid Chemical class C1CCCC1C(C(O)=O)=C(CCCC)N1CCCCC1 JAIYKLJZOBJGSG-UHFFFAOYSA-N 0.000 title 1
- 229940126062 Compound A Drugs 0.000 claims 10
- 229920000858 Cyclodextrin Chemical class 0.000 claims 10
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 7
- 229960004853 betadex Drugs 0.000 claims 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 5
- 239000001116 FEMA 4028 Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- -1 1-pyridinyl Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 비치환 또는 치환된 α-, β-또는 γ-시클로댁스트린 또는 그의 수화물과 함께[1R-[1α(Z),2β,3β,5α]-(+)-7-[5-[[1,1-비페닐)-4-일]메톡시]-3-히드록시-2-(1-피레리디닐)시클로펜틸]-4-헵텐산(화합물 A)또는 그의 염산염으로 되는 수용성 제제.
- 제 1 항에 있어서, 화합물 A가 그의 염산염으로서 사용되는 제제.
- 제 1 항 또는 제 2 항에 있어서, 시클로댁스트린이 β-시클로댁스트린인 방법.
- 상기 임의의 항에서 주사용으로 적합한 형태의 제제.
- 제 4 항에 있어서, 제제가 화합물 A의 염산염 각 1몰에 대하여 적어도 약 1.2몰의 β-시클로댁스트린을 함유하는, 약 생리 pH에서 화합물A의 염산염 및 β-시클로댁스트린 또는 그의 수화물로 되는 맑은 수용성 제제.
- 제 5 항에 있어서, 화합물A의 염산 대 β-시클로댁스트린의 몰 비가 약 1 : 1.4인 제제.
- 제 4 항 - 제6 항중 임의의 항에 있어서, pH가 약 6.0인 제제.
- 제 4 항-제 8 항중 임의의 항에 있어서, 또한 수산화나트륨으로 되는 제제.
- 제 4 항-제 8 항중 임의의 항에 있어서, 유리 염기로서 표시되는 화합물A 또는 그의 염산염의 농도가 0,1-5mg/ml인 제제.
- 제 4 항-제 8 항중 임의의 항에 있어서, 유리 염기로서 표시되는 화합물 또는 그의 염산염의 농도가 0.1-0.2mg/ml인 연속 주입용으로 적합한 형태의 제제.
- 상기 임의의 항에 있어서, 화합물 A또는 그이 염산염을 물 중의 잔존하는 성분과 혼합시킴으로 되는 제제의 제조방법.
- 화합물 A 또는 그의 염산염과 비치환 또는 치환된 α-,β- 또는 γ-시클로댁스트린과의 복합체.
- 화합물 A 대 β-시클로댁스트린의 몰 비가 약 1 : 1인, 화합물 A와 β-시크로댁스트린과의 복합체.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8729823 | 1987-12-22 | ||
| GB878729823A GB8729823D0 (en) | 1987-12-22 | 1987-12-22 | Complexes |
| GB8804422 | 1988-02-25 | ||
| GB888804422A GB8804422D0 (en) | 1988-02-25 | 1988-02-25 | Complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR890009402A true KR890009402A (ko) | 1989-08-01 |
Family
ID=26293226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880017106A KR890009402A (ko) | 1987-12-22 | 1988-12-21 | 피페리디닐시클로펜틸헵텐산 유도체를 함유한 수용성 제제 |
Country Status (29)
| Country | Link |
|---|---|
| JP (1) | JPH02210A (ko) |
| KR (1) | KR890009402A (ko) |
| CN (1) | CN1034132A (ko) |
| AT (1) | AT395943B (ko) |
| AU (1) | AU615245B2 (ko) |
| BE (1) | BE1001704A3 (ko) |
| CA (1) | CA1328078C (ko) |
| CH (1) | CH676665A5 (ko) |
| DE (1) | DE3843059A1 (ko) |
| DK (1) | DK712888A (ko) |
| ES (1) | ES2011727A6 (ko) |
| FI (1) | FI885920A (ko) |
| FR (1) | FR2624731B1 (ko) |
| GB (1) | GB2211737B (ko) |
| GR (1) | GR880100854A (ko) |
| HU (1) | HU204700B (ko) |
| IE (1) | IE61995B1 (ko) |
| IL (1) | IL88764A0 (ko) |
| IT (1) | IT1224835B (ko) |
| LU (1) | LU87411A1 (ko) |
| MY (1) | MY103952A (ko) |
| NL (1) | NL8803126A (ko) |
| NO (1) | NO885689L (ko) |
| NZ (1) | NZ227446A (ko) |
| PH (1) | PH24982A (ko) |
| PL (1) | PL276595A1 (ko) |
| PT (1) | PT89301B (ko) |
| SE (1) | SE502288C2 (ko) |
| ZW (1) | ZW18088A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814725D0 (en) * | 1988-06-21 | 1988-07-27 | Glaxo Group Ltd | Medicaments |
| AU616571B2 (en) * | 1988-10-28 | 1991-10-31 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
| IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| KR100825736B1 (ko) * | 2005-12-07 | 2008-04-29 | 한국전자통신연구원 | 무선 ｘｍｌ 전자 서명 서비스 제공 장치 및 그 방법 |
| KR100832740B1 (ko) * | 2007-01-17 | 2008-05-27 | 한국과학기술원 | 분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS503362B1 (ko) * | 1970-06-10 | 1975-02-04 | ||
| JPS5443569B2 (ko) * | 1972-07-05 | 1979-12-20 | ||
| HU181703B (en) * | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
| JPS57183772A (en) * | 1981-04-29 | 1982-11-12 | Glaxo Group Ltd | Aminocyclopentanol acids and esters, manufacture and medicinal composition |
| JPS58116423A (ja) * | 1981-12-28 | 1983-07-11 | Sumitomo Chem Co Ltd | メタノプロスタサイクリン製剤組成物 |
| JPS58192821A (ja) * | 1982-04-30 | 1983-11-10 | Dainippon Pharmaceut Co Ltd | 脳神経細胞の酸素欠乏性疾患の治療剤 |
| JPS5946228A (ja) * | 1982-09-08 | 1984-03-15 | Zeria Shinyaku Kogyo Kk | 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法 |
| JPS5973576A (ja) * | 1982-09-16 | 1984-04-25 | グラクソ・グル−プ・リミテツド | ピペリジニルシクロペンタノ−ルヘプテン酸塩 |
| GB2127406B (en) * | 1982-09-16 | 1986-03-05 | Glaxo Group Ltd | Piperidinlycyclopentanolheptenoic acid salt |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| JPS60150039A (ja) * | 1984-01-17 | 1985-08-07 | Minolta Camera Co Ltd | 水陸両用固定焦点カメラ |
| DE3504044A1 (de) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel |
| JPS6327440A (ja) * | 1986-07-18 | 1988-02-05 | Sanraku Inc | グルコシル化分岐シクロデキストリン含有組成物 |
-
1988
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/ko not_active Application Discontinuation
- 1988-12-21 SE SE8804607A patent/SE502288C2/sv not_active IP Right Cessation
- 1988-12-21 FI FI885920A patent/FI885920A/fi not_active Application Discontinuation
- 1988-12-21 LU LU87411A patent/LU87411A1/fr unknown
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 HU HU886537A patent/HU204700B/hu not_active IP Right Cessation
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 CN CN88108916A patent/CN1034132A/zh active Pending
- 1988-12-21 PT PT89301A patent/PT89301B/pt not_active IP Right Cessation
- 1988-12-21 NL NL8803126A patent/NL8803126A/nl not_active Application Discontinuation
- 1988-12-21 NZ NZ227446A patent/NZ227446A/xx unknown
- 1988-12-21 FR FR8816902A patent/FR2624731B1/fr not_active Expired - Fee Related
- 1988-12-21 NO NO88885689A patent/NO885689L/no unknown
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 ES ES8803876A patent/ES2011727A6/es not_active Expired - Fee Related
- 1988-12-21 IT IT8848702A patent/IT1224835B/it active
- 1988-12-21 BE BE8801423A patent/BE1001704A3/fr not_active IP Right Cessation
- 1988-12-21 GR GR880100854A patent/GR880100854A/el unknown
- 1988-12-21 DE DE3843059A patent/DE3843059A1/de not_active Ceased
- 1988-12-21 JP JP63320759A patent/JPH02210A/ja active Pending
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/xx unknown
- 1988-12-21 DK DK712888A patent/DK712888A/da not_active Application Discontinuation
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 PL PL27659588A patent/PL276595A1/xx unknown
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 AT AT0313088A patent/AT395943B/de not_active IP Right Cessation
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-22 IL IL88764A patent/IL88764A0/xx not_active IP Right Cessation
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR870002842A (ko) | 싸이클로덱스트린으로 제조되는 7-이소프로폭시-이소플라본의 함유착물과 그를 활성성분으로 함유하는 약리학적 조성물 및 제제 | |
| KR950016717A (ko) | 제약 조성물 | |
| CA2359646C (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method | |
| EP0300526A3 (en) | Antiviral pharmaceutical compositions containing cyclodextrins | |
| ATE271863T1 (de) | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren | |
| EP0327766A3 (en) | Redox systems for brain-targeted drug delivery | |
| HUP0004924A2 (hu) | Ciklodextrineket tartalmazó gyógyászati készítmények | |
| EP0662320A4 (en) | DRY GEL COMPOSITION. | |
| IE823020L (en) | Anti-inflammatory ophthalmic solution | |
| ATE83924T1 (de) | Ibuprofen-cyclodextrin-einschlusskomplexe enthaltende pharmazeutische zubereitungen. | |
| KR940002301A (ko) | 5,10-메틸렌테트라히드로폴산-시클로덱스트린 포접 화합물 | |
| RS20060169A (en) | Process for preparing water soluble diterpens and their applications | |
| KR890009402A (ko) | 피페리디닐시클로펜틸헵텐산 유도체를 함유한 수용성 제제 | |
| EA199600024A3 (ru) | Жидкая стабильная фармацевтическая композиция, содержащая уратоксидазу и лиофилизат для её получения | |
| NO307570B1 (no) | Inklusjonskomplekser oppnådd fra nimesulidalkali- og nimesulidjordalkalisalter og cyklodekstriner eller cyklodekstrinderivater, samt farmasøytisk preparat inneholdende nevnte inklusjonskompleks og fremgangsmåte for å fremstille samme | |
| KR900017594A (ko) | 자궁수축에 대한 15-케토-프로스타글란딘 e 또는 f화합물의 용도 | |
| BR0215848A (pt) | Complexos de inclusão de butilfitalida com ciclodextrina ou seus derivados, processo para preparação destes e uso dos mesmos | |
| DE3863859D1 (de) | Stabile, injizierbare loesungen von salzen von vincristin. | |
| AU613769B2 (en) | Shampoo composition | |
| KR920701183A (ko) | 3-모르폴리노-시드노니민 또는 그 염들 또는 그 토우토머(tautomer)이 성질체를 함유하는 복합체들 및 그 제조방법과 이들을 함유하는 약제학적 조성물 | |
| DE60004768D1 (de) | Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten | |
| KR920702674A (ko) | 신규 시클로덱스트린 포접 착물 | |
| Müller et al. | Cyclodextrin Derivatives for Solubilisation, Stabilisation, and Absorption of Drugs | |
| KR970058709A (ko) | 엘-무스콘(l-muscone)의 포접화합물 및 그의 제조방법 | |
| MXPA01007291A (en) | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-&bgr;-CYCLODEXTRIN OR 2-HYDROXYPROPYL-&bgr;-CYCLODEXTRIN AND METHOD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |